Treatment to reduce vascular calcification in hemodialysis patients using vitamin K (Trevasc-HDK): A study protocol for a randomized controlled trial

Sabrina-Wong-Peixin Haroon, Bee-Choo Tai, Lieng-Hsi Ling, Lynette Teo, Andrew Davenport, Leon Schurgers, Boon-Wee Teo, Priyanka Khatri, Ching-Ching Ong, Sanmay Low, Xi-Er Yeo, Jia-Neng Tan, Srinivas Subramanian, Horng-Ruey Chua, Swee-Yaw Tan, Weng-Kin Wong, Titus-Wai-Leong Lau, Sabrina-Wong-Peixin Haroon, Bee-Choo Tai, Lieng-Hsi Ling, Lynette Teo, Andrew Davenport, Leon Schurgers, Boon-Wee Teo, Priyanka Khatri, Ching-Ching Ong, Sanmay Low, Xi-Er Yeo, Jia-Neng Tan, Srinivas Subramanian, Horng-Ruey Chua, Swee-Yaw Tan, Weng-Kin Wong, Titus-Wai-Leong Lau

Abstract

Introduction: End stage renal failure patients on hemodialysis have significant vascular calcification This is postulated to be related to sub-clinical vitamin K deficiency, which is prevalent in hemodialysis patients. Vitamin K deficiency result in the failure of the matrix GLA protein (MGP) to undergo carboxylation. MGP is a natural local inhibitor of vascular calcification and the lack of functional carboxylated MGP may contribute to increase vascular calcification. Vitamin K supplement should therefore correct this anomaly and decrease the rate or severity of vascular calcification in this population of patients on long-term maintenance hemodialysis. Our study seeks to evaluate the prevalence and the progression of vascular calcification in a cohort of maintenance hemodialysis patients. It will also evaluate the efficacy of vitamin K supplementation in reducing the progression of vascular calcification in this group of patients.

Methods: This will be a single-center randomized, prospective and open-label interventional clinical trial of end stage renal failure patients on hemodialysis. We aim to recruit 200 patients. Eligible patients will be randomized to either the standard care arm or active treatment arm. Active treatment arm patients will receive standard care plus supplementation with oral vitamin K2 isoform 360 mcg 3 times weekly for a total duration of 18 months. Primary outcome measured will be absolute difference in coronary artery calcification score at 18-month between control and intervention arms. Secondary outcomes will be to compare absolute difference in aortic valve calcification, percentage of patients with regression of coronary artery calcification of at least 10%, absolute difference in aortic and systemic arterial stiffness, mortality from any cause and major adverse cardiovascular over the same period.

Discussion: Evidence of successful regression or retardation of vascular calcification will support the conduct of larger and longer-term trials aimed at reducing cardiovascular disease mortality and major adverse cardiovascular events in this high-risk population using a safe and inexpensive strategy TRIAL REGISTRATION:: ClinicalTrials.gov NCT02870829. Registered on 17 August 2016 - Retrospectively registered, https://ichgcp.net/clinical-trials-registry/NCT02870829National University Hospital's Institutional Review Board (2015/01000).

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Flow chart of the trial.
Figure 2
Figure 2
Study schedule of assessment.

References

    1. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342:1478–83..
    1. Raggi P, Boulay A, Chasan-Taber S, et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002;39:695–701..
    1. Matsuoka M, Iseki K, Tamashiro M, et al. Impact of high coronary artery calcification score (CACS) on survival in patients on chronic hemodialysis. Clin Exp Nephrol 2004;8:54–8..
    1. Mizobuchi M, Dwight Towler D, Slatopolsky E. Vascular calcification: the killer of patients with chronic kidney disease. J Am Soc of Nephrol 2009;20:1453–64..
    1. Shroff R, Long DA, Shanahan C. Mechanistic insights into vascular calcification in chronic kidney disease. J Am Soc of Nephrol 2013;24:179–89..
    1. London GM, Marchais SJ, Guérin AP, et al. Arteriosclerosis, vascular calcifications and cardiovascular disease in uremia. Curr Opin Nephrol Hypertens 2005;14:525–31..
    1. Schlieper G, Schurgers L, Brandenburg V, et al. Vascular calcification in chronic kidney disease: an update. Nephrol Dial Transplant 2016;31:31–9..
    1. Nigwekar SU, Thadhani R, Brandenburg VM, et al. Calciphylaxis. N Eng J Med 2018;378:1704–14..
    1. Shroff RC, Shah V, Hiorns MP, et al. The circulating calcification inhibitors, fetuin-A and osteoprotegerin, but not matrix Gla protein, are associated with vascular stiffness and calcification in children on dialysis. Nephrol Dial Transplant 2008;23:3263–71..
    1. Viegas CS, Santos L, Macedo AL, et al. Chronic kidney disease circulating calciprotein particles and extracellular vesicles promote vascular calcification: a role for GRP (Gla-Rich Protein). Arterioscler Thromb Vasc Biol 2018;38:575–87..
    1. Evrard S, Delanaye P, Kamel S, et al. Vascular calcification: from pathophysiology to biomarkers. Clinica Chimica Acta 2015;438:401–14..
    1. Malhotra R, Burke MF, Martyn T, et al. Inhibition of bone morphogenetic protein signal transduction prevents the medial vascular calcification associated with matrix Gla protein deficiency. PLoS One 2015;10:e0117098.
    1. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomized placebo-controlled trial. Lancet 2011;377:2181–92..
    1. Wanner C, Krane V, März W, et al. (German Diabetes and Dialysis Study Investigators). Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353:238–48..
    1. Moe SM, Chen NX. Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol 2008;19:213–6..
    1. Reynolds JL, Joannides AJ, Skepper JN, et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol 2004;15:2857–67..
    1. Ketteler M. Fetuin-A and extraosseous calcification in uremia. Curr Opin Nephrol Hypertens 2005;14:337–42..
    1. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245–52..
    1. Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005;68:1815–24..
    1. Raggi P, Chertow G, Torres PU, et al. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 2011;26:1327–39..
    1. EVOLVE Trial Investigators Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 2012;367:2482–94..
    1. Proudfoot D, Shanahan CM. Molecular mechanisms mediating vascular calcification: role of matrix Gla protein. Nephrology 2006;11:455–61..
    1. Schurgers LJ, Cranenburg EC, Vermeer C. Matrix Gla-protein: the calcification inhibitor in need of vitamin K. Thromb Haemost 2008;100:593–603..
    1. Theuwissen E, Smit E, Vermeer C. The role of vitamin K in soft-tissue calcification. Adv Nutr 2012;3:166–73..
    1. Murshed M, Schinke T, McKee MD, et al. Extracellular matrix mineralization is regulated locally; different roles of two gla-containing proteins. J Cell Biol 2004;165:625–30..
    1. Luo G, Ducy P, McKee MD, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997;386:78–81..
    1. Westenfeld R, Krueger T, Schlieper G, et al. Effect of vitamin K2 supplementation on functional vitamin k deficiency in hemodialysis patients: a randomized trial. Am J Kidney Dis 2012;59:186–95..
    1. Shearer MJ, Newman P. Metabolism and cell biology of vitamin K. Thromb Haemost 2008;100:530–47..
    1. Sumi H. Accumulation of vitamin K2 (menaquinone-7) in plasma after ingestion of Natto and Natto Bacilli (B. Subtilis natto). Food Sci Technol Res 1999;5:48–50..
    1. McCann JC, Ames BN, Vitamin K. an example of triage theory: is micronutrient inadequacy linked to diseases of aging? Am J Clin Nutr 2009;90:889–907..
    1. Oikonomaki T, Papasotiriou M, Ntrinias T, et al. The effect of vitamin K2 supplementation on vascular calcification in haemodialysis patients: a 1-year follow-up randomized trial. Int Urol Nephrol 2019;51:2037–44..
    1. Krueger T, Schlieper G, Schurgers L, et al. Vitamin K1 to slow vascular calcification in hemodialysis patients (VitaVasK trial): a rationale and study protocol. Nephrol Dial Transplant 2014;29:1633–8..
    1. Holden RM, Booth SL, Day AG, et al. Inhibiting the progression of arterial calcification with vitamin K in HemoDialysis patients (iPACK-HD) trial: rationale and study design for a randomized trial of vitamin K in patients with end stage kidney disease. Can J Kidney Health Dis 2015;2:53.
    1. De Vriese AS, Caluwé R, Pyfferoen L, et al. Multicenter randomized controlled trial of vitamin K antagonist replacement by rivaroxaban with or without vitamin K2 in hemodialysis patients with atrial fibrillation: the Valkyrie Study. J Am Soc Nephrol 2020;31:186–96..
    1. Chan A-W, Tetzlaff JM, Gøtzsche PC, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ 2013;346:e7586.
    1. Delanaye P, Krzesinski JM, Warling X, et al. Dephosphorylated-uncarboxylated Matrix Gla protein concentration is predictive of vitamin K status and is correlated with vascular calcification in a cohort of hemodialysis patients. BMC Nephrol 2014. Dec 1;15:145.
    1. Chirinos JA. Arterial stiffness: basic concepts and measurement techniques. J Cardiovasc Transl Res 2012;5:243–55..
    1. Van Bortel LM, Laurent S, Boutouyrie P, et al. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. J Hypertens 2012;30:445–8..
    1. Chen CH, Nevo E, Fetics B, et al. Estimation of central aortic pressure waveform by mathematical transformation of radial tonometry pressure: Validation of generalized transfer function. Circulation 1997;95:1827–36..
    1. Pauca AL, O’Rourke MF, Kon ND. Prospective evaluation of a method for estimating ascending aortic pressure from the radial artery pressure waveform. Hypertension 2001;38:932–7..
    1. Murgo JP, Westerhof N, Giolma JP, et al. Aortic input impedance in normal man: relationship to pressure wave forms. Circulation 1980;62:105–16..
    1. Moe SM, O’Neill KD, Fineberg N, et al. Assessment of vascular calcification in ESRD patients using spiral CT. Nephrol Dial Transplant 2003;18:1152–8..
    1. Agatston AS, Janowitz WR, Hildner FJ, et al. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990;15:827–32..
    1. Singapore renal registry annual report 2015. National Disease Registry Office. Available at: . Accessed May 1, 2016.
    1. United States Renal Data System 2015. Available at: . Accessed May 1, 2016.
    1. Isakova T, Nickolas TL, Denburg M, et al. KDOQI US commentary on the 2017 KDIGO clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD-MBD). Am J Kidney Dis 2017;70:737–51..
    1. Koulaouzidis G, Nicoll R, MacArthur T, et al. Coronary artery calcification correlates with the presence and severity of valve calcification. Int J Cardiol 2013;168:5263–6..
    1. Guo J, Fujiyoshi A, Willcox B, et al. Increased aortic calcification is associated with arterial stiffness progression in multiethnic middle-aged men. Hypertension 2017;69:102–8..
    1. Caluwé R, Vandecasteele S, Van Vlem B, et al. Vitamin K2 supplementation in haemodialysis patients: a randomized dose-finding study. Nephrology Dialysis Transplantation 2014;29:1385–90..

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться